recruited. They will use the existing piloted checklist and will each review three selected papers. We will assess the interrater variability using standard methods (Cohen's Kappa K). If time permits we will also estimate the test-retest reliability. RESULTS: This presentation will introduce the checklist and its dimensions. NMAs can be presented in a variety of ways. We present a selection of formats and how they relate to our checklist. This validation study will show if our checklist is robust and reliably covers the necessary dimensions.
PRIMARY TRACK: Guideline development SECONDARY TRACK: Accrediting guideline developers BACKGROUND (INTRODUCTION): Cow milk allergy (CMA) has an incidence of 1.9% to 4.9% during infancy. The World Allergy Organization initiated the development of DRACMA guidelines to provide therapeutic and diagnostic recommendations for the management of this disease.
LEARNING OBJECTIVES (TRAINING GOALS):
1. Describe a novel process of developing diagnostic guidelines with an international panel. 2. Assess the applicability of various diagnostic tests in the diagnosis of IgE-mediated CMA in comparison with the reference test, an oral food challenge (OFC). METHODS: A multidisciplinary guideline panel including 22 members followed the GRADE approach to formulate recommendations. The panel formulated specific questions about the use of skin prick test (SPT), measurement of milk-specific IgE, and allergen microarrays. Panel members rated the importance of patient consequences as having or not a CMA. A systematic review of studies which evaluated the diagnostic accuracy of these tests compared to an OFC was performed. Evidence summaries have shown patient consequences of using each of the tests with low, average, and high initial probability of CMA. Based on this information DRACMA guideline panel made several recommendations about using SPT and measuring milk-specific IgE in the diagnosis of CMA.
RESULTS:
We identified 26 studies that assessed the accuracy of SPT and 25 studies that assessed the use of milkspecific IgE. Overall quality of evidence supporting the recommendations was low to very low. DRACMA panel made 13 recommendations to use or not to use SPT and/or milk-specific IgE in distinct clinical circumstances. Each recommendation was supplemented by a statement of values and preferences that the panel assumed making judgments about the balance between the desirable and undesirable consequences of using the tests.
DISCUSSION (CONCLUSION):
The GRADE approach creates a link between surrogate outcomes of diagnostic accuracy and patient important outcomes required for decision making that is based on transparent judgments. Our approach provides a process that allows guideline panels to make their process transparent, a key feature of evidence-based guidelines. TARGET AUDIENCE(S): 1. Clinical researcher 2. Evidence synthesizer, developer of systematic reviews or meta-analyses 3. Guideline developer 4. Guideline implementer 5. Developer of guideline-based products 6. Quality improvement manager/facilitator 7. Medical educator 8. Health care policy analyst/policymaker 9. Health insurance payers and purchasers 10. Medical providers and executives 11. Allied health professionals 12. Consumers' and patients' representatives 13. Nurses
